Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib

European Journal of Cancer

Volumn 51, Issue 7, 2015, Pages 852-860

  Lee, Chee Khoon ^a   Goldstein, David ^b,m   Gibbs, Emma ^a   Joensuu, Heikki ^c   Zalcberg, John ^d   Verweij, Jaap ^e   Casali, Paolo G ^f   Maki, Robert G ^g   Cioffi, Angela ^g   McArthur, Grant ^h   Lord, Sarah J ^a,i   Yip, Desmond ^j,k   Kanjanapan, Yada ^j   Rutkowski, Piotr ^l  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d MONASH UNIVERSITY   (Australia)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ School of Medicine University of Norte Dame   (Australia)

^j CANBERRA HOSPITAL   (Australia)

^k The Australian National University   (Australia)

^l INSTITUTE OF ONCOLOGY   (Poland)

^m UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

Gastrointestinal stromal; Imatinib; Nomogram; Prognosis; tumour

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CALIBRATION; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE; HUMAN; MALE; METASTASIS; MITOSIS RATE; NOMOGRAM; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; ADOLESCENT; CLINICAL TRIAL; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NOMOGRAMS; PIPERAZINES; PROGNOSIS; PYRIMIDINES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84927534615     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.02.015     Document Type: Article

References (23)

1. S. Hirota, K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, and S. Ishiguro Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 5350 1998 577 580
2. M.C. Heinrich, K. Owzar, C.L. Corless, D. Hollis, E.C. Borden, and C.D.M. Fletcher Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group J Clin Oncol 26 33 2008 5360 5367
3. C.D. Blanke, G.D. Demetri, M. von Mehren, M.C. Heinrich, B. Eisenberg, and J.A. Fletcher Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 4 2008 620 625
4. M. Van Glabbeke, J. Verweij, P.G. Casali, A. Le Cesne, P. Hohenberger, and I. Ray-Coquard Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European organisation for research and treatment of cancer-italian sarcoma group-australasian gastrointestinal trials group study J Clin Oncol 23 24 2005 5795 5804
5. C.D.M. Fletcher, J.J. Berman, C. Corless, F. Gorstein, J. Lasota, and B.J. Longley Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 5 2002 459 465
6. M. Miettinen, W.E. El-Rifai, H. Sobin, and J. Lasota Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review Hum Pathol 33 5 2002 478 483
7. M. Miettinen, and J. Lasota Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis Arch Pathol Lab Med 130 10 2006 1466 1478
8. H. Joensuu, A. Vehtari, J. Riihimäki, T. Nishida, S.E. Steigen, and P. Brabec Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts Lancet Oncol 13 3 2012 265 274
9. C.L. Corless, K.V. Ballman, C.R. Antonescu, V. Kolesnikova, R.G. Maki, and P.W.T. Pisters Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial J Clin Oncol 2014
10. H. Joensuu, M. Eriksson, K.S. Hall, J.T. Hartmann, D. Pink, and J. Schütte Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib Cancer 120 15 2014 2325 2333
11. J.S. Gold, M. Gönen, A. Gutiérrez, J.M. Broto, X. García-del-Muro, and T.C. Smyrk Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis Lancet Oncol 10 11 2009 1045 1052
12. S. Rossi, R. Miceli, L. Messerini, I. Bearzi, G. Mazzoleni, and C. Capella Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables Am J Surg Pathol 35 11 2011 1646 1656 http://dx.doi.org/10.1097/PAS.0b013e31822d63a7
13. M. Debiec-Rychter, R. Sciot, A. Le Cesne, M. Schlemmer, P. Hohenberger, and A.T. van Oosterom KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Eur J Cancer 42 8 2006 1093 1103
14. J. Verweij, P.G. Casali, J. Zalcberg, A. LeCesne, P. Reichardt, and J.-Y. Blay Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 9440 2004 1127 1134
15. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 282 1958 457 481
16. Harrell FE, Lee KL. Verifying assumptions of the Cox proportional hazards model. In: Proceedings of the eleventh annual SAS Users group international conference; 1986; Cary, N.C: SAS Institute, Inc; 1986. p. 823-8.
17. F.E. Harrell, K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 4 1996 361 387
18. S. May, D. Hosmer, N. Balakrishnan, and C. Rao Hosmer and Lemeshow type goodness-of-fit statistics for the Cox proportional hazards model 2004 Elsevier Amsterdam, North-Holland
19. M.W. Kattan, and P.T. Scardino Prediction of progression: nomograms of clinical utility Clin Prostate Cancer 1 2 2002 90 96
20. B.E. Kiely, Y.Y. Soon, M.H.N. Tattersall, and M.R. Stockler How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials J Clin Oncol 29 4 2011 456 463
21. A. Agaimy Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting Int J Clin Exp Pathol 3 5 2010 461 471
22. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(suppl. 3):iii21-iii26.
23. P. Lagarde, G. Pérot, A. Kauffmann, C. Brulard, V. Dapremont, and I. Hostein Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors Clin Cancer Res 18 3 2012 826 838